Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2013 (2013), Article ID 234391, 4 pages
http://dx.doi.org/10.1155/2013/234391
Case Report

Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation

Department of Medical Oncology, Faculty of Medicine, Adnan Menderes University, 09010 Aydın, Turkey

Received 13 July 2013; Accepted 2 September 2013

Academic Editors: L. Beex, J. I. Mayordomo, and O. Ozyilkan

Copyright © 2013 Esin Oktay et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Tomasello, P. L. Bedard, E. de Azambuja, D. Lossignol, D. Devriendt, and M. J. Piccart-Gebhart, “Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib,” Critical Reviews in Oncology/Hematology, vol. 75, no. 2, pp. 110–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Metro, J. Foglietta, M. Russillo et al., “Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine,” Annals of Oncology, vol. 22, no. 3, pp. 625–630, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Yarden, “The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities,” European Journal of Cancer, vol. 37, supplement 4, pp. S3–S8, 2001. View at Google Scholar · View at Scopus
  4. Z. Gabos, R. Sinha, J. Hanson et al., “Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5658–5663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Gril, D. Palmieri, J. L. Bronder et al., “Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain,” Journal of the National Cancer Institute, vol. 100, no. 15, pp. 1092–1103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. N. U. Lin, L. A. Carey, M. C. Liu et al., “Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 1993–1999, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. N. U. Lin, V. Dieras, D. Paul et al., “EGF105084, a phase II study of lapatinib for brain metastases in patients with HER2+ breast cancer following trastuzumab based systemic therapy and cranial radiotherapy,” Journal of Clinical Oncology, vol. 25, supplement, no. 18, 2007. View at Google Scholar
  8. N. U. Lin, D. Paul, V. Dieras et al., “Lapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer: an updated analysis from EGF105084,” in Proceedings of the 30th Annual San Antonio Breast Cancer Symposium (SABCS '07), San Antonio, Tex, USA, December 2007.
  9. T. Bachelot, G. Romieu, M. Campone et al., “Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study,” The Lancet Oncology, vol. 14, no. 1, pp. 64–71, 2013. View at Google Scholar
  10. D. Cameron, M. Casey, M. Press et al., “A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 533–543, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Greil, S. Borštnar, K. Petráková et al., “Combination therapy of lapatinib and capecitabine for ErbB2-positive metastatic or locally advanced breastcancer: results from the lapatinib expanded accessprogram (LEAP) in central and Eastern Europe,” Onkologie, vol. 34, no. 5, pp. 233–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. N. U. Lin, W. Eierman, R. Greil et al., “Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases,” Journal of Neuro-Oncology, vol. 105, no. 3, pp. 613–620, 2011. View at Publisher · View at Google Scholar · View at Scopus